![]() |
Sign Up! | Tags | Domains | Statistics | Options | Advanced Search |
Tagged: nvs, novartis, research and development, manufacturers and mergers
Cytos Biotechnology AG (SWX: CYTN) has entered into an exclusive global commercial license agreement with Novartis (NYSE:NVS) for the development, manufacturing and commercialization of CYT002-NicQb – a novel therapeutic vaccine under phase II clinical development for the treatment of nicotine addiction. The terms of agreement include: Novartis is granted world-wide exclusive rights for … Continue Reading »